Drug Profile
Narnatumab
Alternative Names: IMC-RON-8; RON-8Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator ImClone Systems
- Developer Eli Lilly and Company; ImClone Systems
- Class Monoclonal antibodies
- Mechanism of Action RON protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 18 Sep 2013 Discontinued - Phase-I for Solid tumours (late-stage disease) in USA (IV)
- 16 Nov 2011 Pharmacodynamics data from a preclinical trial in Solid tumours presented at the 23rd AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2011)
- 01 May 2010 Phase-I clinical trials in Solid tumours (late-stage disease) in USA (IV)